samedan logo

home > news > detailed info

Ashfield Launches Cell & Gene Therapy Commercialization Network, EmerGENE


14th July
2021Ashfield, part of UDG Healthcare plc, has announced the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries.

The first of its kind in the industry, EmerGENE has been built by a multidisciplinary team that delivers expert-led guidance and services to biotechs throughout their entire clinical to commercial journey.

Combining experts from Ashfield Health, Ashfield Engage, and Ashfield Advisory, EmerGENE aims to unlock the potential of cell and gene therapy, helping drug developers to bring transformational treatments to patients.

Amar Urhekar, Global President at Ashfield Health, said: “At Ashfield, we look to embed ourselves into our customers’ businesses and use our expertise to create tangible solutions which best meet their needs.

“EmerGENE is no different, and with over 1,200 cell and gene therapy clinical trials currently underway globally, and 1,000 different manufacturers exploring cell and gene therapies right now, it’s clear that there is demand for support in this space.

“EmerGENE is the first network approach to offer this unique, end-to-end offering and we’re confident that both new and existing customers will benefit from having access to everything they need from one partner.”

EmerGENE will provide guidance on all areas, including commercialization strategic support, early clinical development guidance, distribution and logistics, market access and patient and HCP engagement and support.

The experts at EmerGENE have supported five of the six current commercialized cell and gene therapy products on their journey to market.

EmerGENE’s Global Lead, Ben Beckley said: “When it comes to cell and gene therapies, we know that every moment matters. In many cases, these therapies are a last chance for patients and their families so helping innovators get their discoveries to patients with as much ease as possible is truly vital work.

“EmerGENE’s perfectly tailored teams bring together entrepreneurial expertise and mentorship alongside logistical and practical capabilities in order to find the correct path – not just providing advice but executing solutions and ultimately realizing the awesome potential of cell and gene therapies for patients and their families.”

EmerGENE’s offering includes:
  • Distribution and logistics
  • Pre-clinical support
  • Commercial and organizational strategies
  • Market access and value Commercial team build-out and support
  • Disease, platform and launch communications
  • Medical information services
  • Patient support programs
Print this page
Send to a friend
News and Press Releases

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery • New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform
More info >>

White Papers

What You Need To Know About Thermal Shipping Technologies

Temptime Corporation

This paper presents highlights from a thermal performance study conducted by Modality Solutions LLC. The study examined the performance of five shipping technologies commonly used by specialty pharmacies to transport high-value refrigerated specialty medicines against an industry accepted temperature profile standard.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement